High-Frequency Ultrasound Imaging for Stage III Cellulite: A Three-Subtype Structural Classification from an Observational Cohort Study

高频超声成像在III期橘皮组织诊断中的应用:一项观察性队列研究的三亚型结构分类

阅读:2

Abstract

INTRODUCTION: Stage III cellulite is traditionally assessed through clinical inspection; however, visual scales often fail to capture the structural complexity of subcutaneous tissue. High-frequency ultrasound (HFUS) provides an objective, non-invasive method for visualizing the architecture of adipose tissue. This study aimed to develop and validate an ultrasound-based subclassification of stage III cellulite to improve diagnostic accuracy and facilitate personalized treatment strategies. METHODS: This observational cohort study included 150 female patients (ages 20-55 years, BMI 18-32 kg/m(2)) with a clinical diagnosis of stage III cellulite. Two physicians independently performed clinical staging (3A/3B) using the Nürnberger-Müller scale. A single physician conducted HFUS examinations of the subgluteal and trochanteric regions using a 20-MHz probe. Ultrasound features, including fat thickness, echotexture, fibrosis, and edema, served to classify patients into three phenotypes: 3A, 3B, and mixed. RESULTS: HFUS identified 50 patients in each subtype. The mean superficial fat thickness was 4.8 ± 1.1 mm in 3A, 11.3 ± 2.4 mm in 3B, and 8.6 ± 3.4 mm in mixed subtype. Severe fibrosis occurred in 100.0% of patients with type 3B, was absent in type 3A, and was variable in the mixed type. Edema was mild in all patients with type 3A (100.0%), severe in 44.0% of those with type 3B, and variable in the mixed group. Discrepancies between clinical and ultrasound classifications appeared in 33.3% of cases. Agreement between classifications was moderate (Gwet's AC1 = 0.444; p < 0.001). CONCLUSION: HFUS provides a valid and reproducible method for structurally assessing advanced cellulite. It enables the identification of a third, clinically unrecognized mixed phenotype, which has significant therapeutic implications by supporting more accurate treatment selection and improving treatment personalization.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。